Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and relaxing, because here we are — once again — facing the usual growing to-do list of online calls and deadlines and the like. But you know, the world keeps spinning, so time to give it an extra push with a useful cup of stimulation. Our choice this morning is maple bourbon. Yes, this is a real thing. Feel free to join us. Meanwhile, here are a few tidbits to get you going. Hope your day goes delightfully, and do keep in touch. …

The leaders of the world’s wealthiest nations and several drug makers took steps to widen equitable access to Covid-19 vaccines, such as issuing voluntary licenses to expand manufacturing, increasing donations to a global distribution program, and investing in production capacity in Africa, STAT writes. But the Rome Declaration lacked consensus on a proposal supported by the U.S. and dozens of low- and middle-income countries to issue a temporary waiver of intellectual property protections.


AstraZeneca (AZN) chief executive officer Pascal Soriot insisted its Covid-19 vaccine has a future, as he revealed the U.K. had priority access to the shot and hit out at the “armchair generals” behind “traumatic” attacks on the drug maker, The Financial Times reports. Soriot also said the company has not decided what to do with the vaccine in the long term. AstraZeneca did not have a traditional vaccine business before the pandemic, selling only a flu vaccine nasal spray.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.